Discover the top abstracts of note for the 2023 ASH annual meeting.
Our oncologists have compiled the top 10 abstracts recently presented at the annual meeting of the
American Society of Clinical Oncology.
A prototype blood-based screening test evaluated by Cleveland Clinic researchers and others can accurately detect and localize multiple types of cancer, often before symptoms show. The promising results raise hopes that the assay will help achieve the long-sought goal of population-scale early detection of cancer.
It is well established that infiltrative renal masses (IRMs) are mostly malignant and aggressive. Yet, until recently, the standard practice in radiology hasn’t been to routinely assess or document IRMs. To better understand the prevalence and significance of IRMs, researchers in the Glickman Urological & Kidney Institute led a new and revealing investigation.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Two studies examine whether adding additional drugs to a standard chemotherapy regimen could improve outcomes for patients with subgroups of B-cell lymphoma.
Classification of lymphomas is complex, but genetic analysis is producing prognosis and treatment insights. While cytotoxic chemotherapy will continue to be a mainstay of diffuse large B cell lymphoma treatment, a variety of targeted approaches is moving quickly into clinical use.
A new mouse model study finds that small molecules bind to ezrin protein to stop large diffuse B-cell lymphomas, providing a possible new treatment for aggressive cancers.